Condition

Suicidal Behavior

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6

Recruiting1

Common interventions7

Lead sponsors shown4

Clinical trials

6 shown

Basal Plasma Lithium Levels and Suicidal EventsNCT05409794 · 2022-12-09

RECRUITING

Neural Correlates of Suicidal Behavior in YouthNCT07568054 · 2026-10-30

NOT_YET_RECRUITING

Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for PsychosisNCT07756567 · 2026-08-01

NOT_YET_RECRUITING

Neuroinflammation, Serotonin, Impulsivity and SuicideNCT02824081 · 2015-11-01

UNKNOWN

Predictors of Suicidal Behavior in DepressionNCT02904005 · 2015-03-01

UNKNOWN

Fluoxetine and Bupropion to Treat Patients With Depression and AlcoholismNCT00449007 · 2006-02-01

TERMINATED

Common interventions

Blood sampleBIOLOGICAL2 bupropionDRUG1 CAMSBEHAVIORAL1 fluoxetineDRUG1 Standard Care (in control arm)BEHAVIORAL1 Standardized assessment on depressed patientsOTHER1 Suicide Prevention InterventionBEHAVIORAL1

Leading sponsors

University Hospital, Montpellier 3 New York State Psychiatric Institute 1 The Cleveland Clinic 1 University of California, San Diego 1

Trial status mix

NOT_YET_RECRUITING2

UNKNOWN2

RECRUITING1

TERMINATED1

Phase mix

NA4

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.